IMPACT OF EVEROLIMUS ON PERICARDIAL AND PLEURAL EFFUSIONS IN DE NOVO HEART TRANSPLANT RECIPIENTS

被引：0
|
作者：
Barten, M.
Zuckermann, A. [1 ]
Arizon, J. M.
Dong, G. [2 ]
Eisen, H.
Kobashigawa, J.
Lehmkuhl, H. B.
Pellegrini, C.
Ross, H.
机构：
[1] Univ Vienna, Vienna, Austria
[2] Novartis Pharmaceut, E Hanover, Vietnam
来源：
TRANSPLANT INTERNATIONAL | 2010年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
0059
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of everolimus vs mycophenolate mofetil (MMF) in de novo heart transplant recipients.
    Tenderich, G
    Dorent, R
    Yang, XL
    Kessabi, S
    Ricci, JF
    Annemans, L
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 251 - 251
  • [32] Everolimus Initiation With Calcineurin Inhibitor Withdrawal Reduces Allograft Vasculopathy in De-Novo Heart Transplant Recipients
    Arora, S.
    Andersson, B.
    Gustafsson, E.
    Eiskjaer, H.
    Radegran, G.
    Aaberge, L.
    Erikstad, I.
    Gude, E.
    Ueland, T.
    Aukrust, P.
    Solbu, D.
    Dellgren, G.
    Andreassen, A.
    Gullestad, L.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S154 - S154
  • [33] Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients
    Lehmkuhl, Hans B.
    Mai, Daniel
    Dandel, Michael
    Knosalla, Christoph
    Hiemann, Nicola E.
    Grauhan, Onnen
    Huebler, Michael
    Pasic, Miralem
    Weng, Yuguo
    Meyer, Rudolph
    Rothenburger, Markus
    Hummel, Manfred
    Hetzer, Roland
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (07): : 700 - 704
  • [34] Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomized Study EVERHEART.
    Potena, L.
    Barberini, F.
    Boffini, M.
    Maiello, C.
    Pedrazzini, G.
    Faggian, G.
    Gerosa, G.
    Lilla, P.
    Marraudino, N.
    Corda, M.
    Bernazzali, S.
    Guarisco, R.
    Livi, U.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 93 - 93
  • [35] Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients
    Choi, Hyo-In
    Kang, Do-Yoon
    Kim, Min-Seok
    Lee, Sang Eun
    Ahn, Jung-Min
    Lee, Jong-Young
    Kim, Yong-Hak
    Park, Duk-Woo
    Jung, Sung-Ho
    Kim, Jae-Joong
    [J]. ATHEROSCLEROSIS, 2022, 357 : 1 - 8
  • [36] DE NOVO EVEROLIMUS- VERSUS MMF-BASED IMMUNOSUPPRESSION IN HEART TRANSPLANT RECIPIENTS: EFFECT ON PROTEINURIA
    Andreassen, A.
    Rinaldi, M.
    Gerosa, G.
    Bara, C.
    Dong, G.
    Lopez, P.
    Segovia, J.
    [J]. TRANSPLANT INTERNATIONAL, 2011, 24 : 66 - 66
  • [37] Pericardial and pleural effusions in decompensated chronic heart failure
    Kataoka, H
    [J]. AMERICAN HEART JOURNAL, 2000, 139 (05) : 918 - 923
  • [38] IMPACT OF EVEROLIMUS ON DE NOVO DONOR-SPECIFIC ANTI-HLA ANTIBODIES IN RENAL TRANSPLANT RECIPIENTS
    Kitajima, Kumiko
    Nakajima, Ichiro
    Fuchinoue, Shohei
    [J]. TRANSPLANT INTERNATIONAL, 2013, 26 : 245 - 245
  • [39] Pseudopericardial effusions in heart transplant recipients
    Dorffner, R
    Metz, VM
    Eibenberger, KL
    Dock, WI
    Hormann, M
    Buxbaum, P
    Grabenwoger, F
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1996, 15 (08): : 846 - 849
  • [40] PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPPRESSIVE THERAPY FOR DE NOVO KIDNEY TRANSPLANT RECIPIENTS IN RUSSIA
    Avxentyev, N. A.
    Derkach, E., V
    Prokopenko, E., I
    [J]. VESTNIK TRANSPLANTOLOGII I ISKUSSTVENNYH ORGANOV, 2019, 21 (01): : 23 - 34
12345